Geneva, Switzerland, May 12, 2025-Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for ...
ADELAIDE, Australia, and CAMBRIDGE, Mass., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in ...
Please provide your email address to receive an email when new articles are posted on . A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and ...
Muscarinic M4 receptor positive allosteric modulators are detailed in an Acadia Pharmaceuticals Inc. patent. They are reported to be useful for the treatment of Alzheimer’s disease, pain, ...
Novel nicotinamide phosphoribosyltransferase (NAMPT) positive allosteric modulators (N-PAMs) have been discovered and evaluated by University of Illinois and University of Arizona investigators.
IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26FDA’s decision follows ...
Please provide your email address to receive an email when new articles are posted on . Change from baseline in gait variability did not differ between groups, regardless of cognitive load. Treatment ...
This new article publication from Acta Pharmaceutica Sinica B, discusses allosteric modulation of G protein-coupled receptors as a novel therapeutic strategy in neuropathic pain. Neuropathic pain is a ...
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results